DRAVP ID  DRAVPc066

Name   Lopinavir

Sequence  Not available

Molecular Formula  C37H48N4O5

Condition/Disease  human immunodeficiency virus (HIV) infection.

Group  Approved

Type  peptidomimetic

Description  Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity.Like many other protease inhibitors (e.g. saquinavir, nelfinavir), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the HIV-1 protease.

Active sequence/Structure 

No comments found.

DrugBank Accession Number  DB01601

Pubchem ID  92727

CHEMBL ID  CHEMBL729

UNII  2494G1JF75

CAS  192725-17-0

Reference  9884314  19108994  9835517  30346663  22762019  21953914